Table 2 Clinical findings in COVID and non-COVID patients
From: The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis?
Clinical findings | Non-COVID group n = 2412 | COVID group n = 180 | p |
|---|---|---|---|
Duration of symptoms (days) | 3.66 (7.52) | 3.71 (6.85) | 0.88 |
Abdominal findings | 0.006 | ||
No pain | 53 (2.2%) | 2 (1.1%) | |
Localized pain | 1510 (62.8%) | 93 (52%) | |
Localized pain and rigidity | 541 (22.5%) | 48 (26.8%) | |
Diffuse abdominal pain | 299 (12.4%) | 36 (20.1%) | |
Peritonitis | 0.002 | ||
Localized | 1520 (95.1%) | 127 (88.2%) | |
Generalized | 78 (4.9%) | 17 (11.8%) | |
Core temperature (°C) | 36.87 (0.81) | 37.32 (0.92) | p < 0.0001 |
Heart rate (bpm) | 84.3 (16.6) | 89.7 (14.8) | p < 0.0001 |
Systolic blood pressure (mmHg) | 131.5 (23.4) | 124 (23.4) | p < 0.0001 |
Respiratory rate (breaths/min) | 17.1 (3.25) | 19.3 (3.73) | p < 0.0001 |
SpO2 (%) | 97 (97–100) | 94 (80–100) | p < 0.0001 |
Shock | 85 (3.5%) | 20 (11.2%) | p < 0.0001 |
Preoperative diagnosis | p = 0.18 | ||
Gallstone cholecystitis | 2177 (90.8%) | 161 (92%) | |
Acalculous cholecystitis | 93 (3.9%) | 8 (4.6%) | |
Biliary pancreatitis | 19 (0.8%) | 2 (1.1%) | |
Gallbladder mucocele | 18 (0.8%) | 0 (0%) | |
CBD stones | 85 (3.5%) | 3 (1.7%) | |
Cholangitis | 4 (0.2%) | 0 (0%) | |
Others | 1 (0.04%) | 1 (0.6%) |